PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations.
Michael V HolmesChristiana KartsonakiRuth BoxallKuang LinNicola ReeveCanqing YuJun LvDerrick A BennettMichael R HillLing YangYiping ChenHuaidong DuIain TurnbullRory CollinsRobert J ClarkeMartin D TobinLiming LiIona Y MillwoodZhengming ChenRobin G Waltersnull nullPublished in: European journal of preventive cardiology (2024)
Genetic analyses of over 100 000 participants of the China Kadoorie Biobank, mimicking the effect of new drugs intended to reduce cholesterol by targeting the PCSK9 protein, have identified potential severe effects of lower PCSK9 activity in patients with existing respiratory disease.PCSK9 genetic variants that are associated with lower cholesterol and reduced rates of cardiovascular disease are also associated with increased risk of a range of respiratory diseases, including asthma, upper respiratory tract infections, and hospitalization with chronic obstructive pulmonary disease (COPD).These genetic variants are not associated with whether or not individuals have COPD; instead, they are specifically associated with an increase in the chance of those who already have COPD being hospitalized and even dying, suggesting that careful monitoring of such patients should be considered during development of and treatment with anti-PCSK9 medication.
Keyphrases
- chronic obstructive pulmonary disease
- low density lipoprotein
- lung function
- respiratory tract
- cardiovascular disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- cystic fibrosis
- healthcare
- chronic kidney disease
- palliative care
- type diabetes
- peritoneal dialysis
- metabolic syndrome
- gene expression
- combination therapy
- patient reported outcomes
- genome wide
- risk assessment
- copy number
- binding protein
- cardiovascular risk factors
- replacement therapy
- cardiovascular events